WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing. In a positive profit alert filed with the Hong Kong stock exchange on Wedne